TY - JOUR
T1 - Radiosurgery or fractionated stereotactic radiotherapy plus whole-brain radioherapy in brain oligometastases a long-term analysis
AU - Balducci, Mario
AU - Autorino, Rosa
AU - Chiesa, Silvia
AU - Mattiucci, Giancarlo
AU - Pompucci, Angelo
AU - Azario, Luigi
AU - D'Agostino, Giuseppe Roberto
AU - Ferro, Milena
AU - Fiorentino, Alba
AU - Fersino, Sergio
AU - Mazzarella, Ciro
AU - Colosimo, Cesare
AU - Frascino, Vincenzo
AU - Anile, Carmelo
AU - Valentini, Vincenzo
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Aim: To analyze the outcome of patients with brain oligometastases treated by radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) after whole-brain radiotherapy (WBRT). Patients and Methods: Overall survival (OS) and local control (LC) were evaluated in patients (patients) with 1-2 brain metastases. Results: Forty-seven patients were selected. They were submitted to WBRT (median dose=3,750 cGy) followed by SRS (17 patients; median dose=1,500 cGy) or FSRT (30 patients; median dose=2,000 cGy). Median follow-up was 102 months (range=17-151); the median survival was 22 months for the SRS group and 16 months for the FSRT group. One-year and 5-year survival was 56% and 16%, respectively, in SRT and 62.1% and 3%, respectively, in FSRT. Neither treatment proved to significantly impact OS (p=0.4). The 1-year LC rates were 80% and 61.1% in the two groups, respectively (p=0.15). Conclusion: SRS or FSRT after WBRT could offer the same outcomes in patients with brain oligometasteses. Further investigation is warranted to confirm these data and define the optimal stereotactic modality.
AB - Aim: To analyze the outcome of patients with brain oligometastases treated by radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) after whole-brain radiotherapy (WBRT). Patients and Methods: Overall survival (OS) and local control (LC) were evaluated in patients (patients) with 1-2 brain metastases. Results: Forty-seven patients were selected. They were submitted to WBRT (median dose=3,750 cGy) followed by SRS (17 patients; median dose=1,500 cGy) or FSRT (30 patients; median dose=2,000 cGy). Median follow-up was 102 months (range=17-151); the median survival was 22 months for the SRS group and 16 months for the FSRT group. One-year and 5-year survival was 56% and 16%, respectively, in SRT and 62.1% and 3%, respectively, in FSRT. Neither treatment proved to significantly impact OS (p=0.4). The 1-year LC rates were 80% and 61.1% in the two groups, respectively (p=0.15). Conclusion: SRS or FSRT after WBRT could offer the same outcomes in patients with brain oligometasteses. Further investigation is warranted to confirm these data and define the optimal stereotactic modality.
KW - Brain oligometastases
KW - Fractionation
KW - RPA
KW - Stereotactic radiotherapy
KW - Whole brain radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=84929698850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929698850&partnerID=8YFLogxK
M3 - Article
C2 - 25964595
AN - SCOPUS:84929698850
VL - 35
SP - 3055
EP - 3060
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 5
ER -